BioCentury
ARTICLE | Product R&D

Local reagent makes good

Genisphere turns old reagents into new nanoparticles, avoids liver

June 2, 2016 7:00 AM UTC

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting lost in the liver.

Today, Genisphere announced a collaborative research, option to license agreement with MedImmune LLC, the biologics unit of AstraZeneca plc - the biotech's first public deal with a major pharma...